Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S.

N Engl J Med. 2003 Jul 17;349(3):247-57.

2.

Carcinoma microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for stage II rectal cancer.

Yang L, Sun Y, Huang XE, Yu DS, Zhou JN, Zhou X, Li DZ, Guan X.

Asian Pac J Cancer Prev. 2015;16(4):1545-51.

3.

Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer.

Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K, Boland CR.

Gastroenterology. 2004 Feb;126(2):394-401.

PMID:
14762775
5.

Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB 3rd, Hamilton SR.

N Engl J Med. 2001 Apr 19;344(16):1196-206.

6.

Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.

Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Piñol V, Xicola RM, Bujanda L, Reñé JM, Clofent J, Bessa X, Morillas JD, Nicolás-Pérez D, Payá A, Alenda C; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association.

Gut. 2006 Jun;55(6):848-55. Epub 2005 Nov 18.

7.

The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.

Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Balaguer F, Sempere L, Xicola RM, Bujanda L, Reñé JM, Clofent J, Bessa X, Morillas JD, Nicolás-Pérez D, Pons E, Payá A, Alenda C; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association.

Eur J Cancer. 2009 Feb;45(3):365-73. doi: 10.1016/j.ejca.2008.07.016. Epub 2008 Aug 21.

PMID:
18722765
8.

Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.

Hemminki A, Mecklin JP, Järvinen H, Aaltonen LA, Joensuu H.

Gastroenterology. 2000 Oct;119(4):921-8.

PMID:
11040179
9.

Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.

Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT.

J Clin Oncol. 2005 Aug 20;23(24):5635-43.

PMID:
16110022
10.

Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instability.

Johnson L, Chu E.

Clin Colorectal Cancer. 2002 Nov;2(3):146-8. Review. No abstract available.

PMID:
12482330
11.

Microsatellite instability and colorectal cancer prognosis.

Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L, Menigatti M, Roncari B, Maffei S, Rossi G, Ponti G, Santini A, Losi L, Di Gregorio C, Oliani C, Ponz de Leon M, Lanza G.

Clin Cancer Res. 2005 Dec 1;11(23):8332-40. Erratum in: Clin Cancer Res. 2006 Jun 15;12(12):3868-9.

12.
13.

Thymidylate synthase expression in colon carcinomas with microsatellite instability.

Sinicrope FA, Rego RL, Halling KC, Foster NR, Sargent DJ, La Plant B, French AJ, Allegra CJ, Laurie JA, Goldberg RM, Witzig TE, Thibodeau SN.

Clin Cancer Res. 2006 May 1;12(9):2738-44.

14.

Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.

Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guilloux A, Wanherdrick K, Dorard C, Taieb A, Saget A, Loh M, Soong R, Zeps N, Platell C, Mews A, Iacopetta B, De Thonel A, Seigneuric R, Marcion G, Chapusot C, Lepage C, Bouvier AM, Gaub MP, Milano G, Selves J, Senet P, Delarue P, Arzouk H, Lacoste C, Coquelle A, Bengrine-Lefèvre L, Tournigand C, Lefèvre JH, Parc Y, Biard DS, Fléjou JF, Garrido C, Duval A.

Gastroenterology. 2014 Feb;146(2):401-11.e1.

PMID:
24512910
15.

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.

Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S.

Ann Oncol. 2015 Jan;26(1):126-32. doi: 10.1093/annonc/mdu499. Epub 2014 Oct 30.

PMID:
25361982
16.

Microsatellite instability in colon cancer.

Allegra CJ, Kim G, Kirsch IR.

N Engl J Med. 2003 Oct 30;349(18):1774-6; author reply 1774-6. No abstract available.

17.

Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer.

Lamberti C, Lundin S, Bogdanow M, Pagenstecher C, Friedrichs N, Büttner R, Sauerbruch T.

Int J Colorectal Dis. 2007 Feb;22(2):145-52. Epub 2006 May 25.

PMID:
16724208
18.

5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

Jover R, Nguyen TP, Pérez-Carbonell L, Zapater P, Payá A, Alenda C, Rojas E, Cubiella J, Balaguer F, Morillas JD, Clofent J, Bujanda L, Reñé JM, Bessa X, Xicola RM, Nicolás-Pérez D, Castells A, Andreu M, Llor X, Boland CR, Goel A.

Gastroenterology. 2011 Apr;140(4):1174-81. doi: 10.1053/j.gastro.2010.12.035. Epub 2010 Dec 24.

19.

Prognostic and predictive relevance of microsatellite instability in colorectal cancer.

Storojeva I, Boulay JL, Heinimann K, Ballabeni P, Terracciano L, Laffer U, Mild G, Herrmann R, Rochlitz C.

Oncol Rep. 2005 Jul;14(1):241-9.

PMID:
15944796
20.

Role of microsatellite instability in the management of colorectal cancers.

Buecher B, Cacheux W, Rouleau E, Dieumegard B, Mitry E, Lièvre A.

Dig Liver Dis. 2013 Jun;45(6):441-9. doi: 10.1016/j.dld.2012.10.006. Epub 2012 Nov 26. Review.

PMID:
23195666

Supplemental Content

Support Center